We report the results of a consecutive series of patients who underwent autologous (auto) (40), allogeneic (allo) (22) or syngeneic transplantation (2) for multiple myeloma (MM) at our centre. Median age at diagnosis was 45.5 (auto) and 43 (allo) years. Most patients had stage 2 (27% auto; 27% allo) or stage 3 (62% auto; 50% allo) disease and 73% demonstrated chemosensitivity prior to transplant. Median time from diagnosis to transplant was 18.6 months (auto) and 16.4 months (allo). Standard conditioning regimens were used. Median time to neutrophil engraftment was 11 days (7–18) (auto) and 18 days (13–24) (allo) and median time to platelet engraftment was 11 days (6–60) and 18 days (13–105), respectively. Ninety-day mortality was 5% (auto) and 27% (allo). Median follow-up was 15 months (6–48) (auto) and 42 months (24–52) (allo). Three-year progression-free survival (PFS) was 17 ± 10% (auto) and 22 ± 9% (allo) and 3-year overall survival (OS) was 74 ± 11% (auto) and 32 ± 10% (allo). Autologous transplantation for MM is a safe procedure with good OS although disease progression following transplant is frequent. Allogeneic transplantation has a high procedure-related mortality and PFS comparable to autologous transplantation but OS is poor. The early mortality and high OS of autologous transplantation in MM compares favourably with both the results of allogeneic transplantation and published results of standard therapy in this retrospective analysis.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
About this article
Cite this article
Couban, S., Stewart, A., Loach, D. et al. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant 19, 783–789 (1997). https://doi.org/10.1038/sj.bmt.1700738
- multiple myeloma
- autologous bone marrow transplantation
- allogeneic bone marrow transplantation
This article is cited by
Current Hematologic Malignancy Reports (2008)
Bone Marrow Transplantation (2007)
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation
Bone Marrow Transplantation (2004)
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
Bone Marrow Transplantation (2003)
Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect
Bone Marrow Transplantation (2001)